← Back to Search

Device

nVNS (gammaCore) for Gastroparesis-Related Nausea (nVNS Trial)

N/A
Waitlist Available
Led By Jay Pasricha, MD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 and 6 weeks after nvns initiation
Awards & highlights

nVNS Trial Summary

This trial is testing whether a handheld device that sends electrical stimulation to the vagus nerve can relieve nausea, with the goal of providing a safer alternative to traditional rescue medications.

Who is the study for?
Adults with gastroparesis or chronic unexplained nausea and vomiting, experiencing moderate to severe symptoms. Participants must have a specific level of nausea documented and can only use certain anti-nausea medications up to four times daily. They cannot have other conditions that explain their symptoms, be pregnant or nursing, use narcotics frequently, have had certain gastrointestinal surgeries or heart issues, or possess any implanted electrical devices.Check my eligibility
What is being tested?
The trial is testing nVNS (gammaCore), a non-invasive device applied on the neck to stimulate the vagus nerve as an alternative treatment for nausea in gastroparesis patients. It aims to provide relief without the risks associated with invasive procedures like Gastric electrical stimulation (GES) and may reduce reliance on traditional rescue medications.See study design
What are the potential side effects?
While not explicitly listed in the provided information, potential side effects of nVNS typically include mild discomfort at the application site, headache, dizziness, or tingling sensation. Serious side effects are rare but could involve changes in blood pressure or heart rhythm.

nVNS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 and 6 weeks after nvns initiation
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 and 6 weeks after nvns initiation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Average daily use of rescue medications for exacerbation of nausea/vomiting.

nVNS Trial Design

1Treatment groups
Experimental Treatment
Group I: nVNS deviceExperimental Treatment1 Intervention
Candidates who, after the screening period are eligible to receive the nVNS device.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
nVNS (gammaCore)
2021
N/A
~50

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,274 Previous Clinical Trials
14,840,472 Total Patients Enrolled
11 Trials studying Gastroparesis
1,183 Patients Enrolled for Gastroparesis
ElectroCore INCIndustry Sponsor
30 Previous Clinical Trials
2,205 Total Patients Enrolled
Jay Pasricha, MDPrincipal InvestigatorJohns Hopkins School of Medicine
1 Previous Clinical Trials
250 Total Patients Enrolled
1 Trials studying Gastroparesis
250 Patients Enrolled for Gastroparesis

Media Library

nVNS (gammaCore) (Device) Clinical Trial Eligibility Overview. Trial Name: NCT04857281 — N/A
Gastroparesis Research Study Groups: nVNS device
Gastroparesis Clinical Trial 2023: nVNS (gammaCore) Highlights & Side Effects. Trial Name: NCT04857281 — N/A
nVNS (gammaCore) (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04857281 — N/A
~11 spots leftby Jun 2025